PerpEquities

Equity

Vaxcyte, Inc. (PCVX) perpetual futures

PCVX perpetual futures on 1 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade PCVXUSDT.

Vaxcyte, Inc. is a clinical-stage biotechnology company developing protein-based vaccines to prevent or manage bacterial infectious diseases, led by its pneumococcal conjugate vaccine candidate VAX-24.

$65.80-8.9%NASDAQ open
Open in terminal

Price chart

Interactive TradingView chart

TradingView symbol NASDAQ:PCVX

Loads TradingView's third-party widget (about 1 MB) on demand.

Auto: underlying reference priceOpen in TradingView

Trading data

Perpetual market activity

1/1 live markets
Venues
1
Live markets
1/1
24h volume
$868.4
Open interest
$1.2K
Best liquidity
$295.7K
Bitget
Tightest spread
+66.7 bps
Bitget
Highest volume
$868.4
Bitget
Settlement mix
USDT · 1/1
Perp/spot vol.
0.00x
Spot volume $229.1M
OI / float
0.00%
Float $8.7B
Spot performance
1D-9.20%
5D+18.16%
1M+9.60%
6M+12.05%
YTD+45.28%
1Y+62.65%

Venue matrix

1 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
BitgetTradePCVX/USDTTrading$65.800.0% APR
0.000% every 8h
+66.7 bps$295.7K$868.4$1.2KUSDT20x

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

Thin liquidity · 1 of 1 venues absorb $10k · Typical cost: +42.9 bps

Cheapest execution: Bitget · +42.9 bps

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

PCVX

Tightest spread

PCVX

Highest volume

PCVX

Funding history

Stored venue snapshots by market

Company data

Company fundamentals

Updated 1h ago
Market cap
$9.7B
Updated 1h ago
Revenue
$0
Trailing 12 months
Revenue growth
-
Next fiscal year
Profit margin
0.0%
P/E
-8.8
Peer P/E -0.4
Free cash flow
-$1.2B
Trailing 12 months
More metrics
Net income
-$1.1B
Trailing 12 months
P/S
-
Peer P/E
-0.4
Similar listed perps
Revenue estimate
$25M
Next fiscal year
Earnings
2026-11-03
Revenue est. $12.5M · Updated 1h ago
Dividend
-

Fundamental detail

Annual + quarterly
Latest revenue$0
Net margin0.0%
Free cash flow-$669.3M
Net debt$54.9M
2020$0
2021$0
2022$0
2023$0
2024$0
2025$0
PeriodRevenueGrowthNet incomeFCF
2020$0--$89.2M-$47.8M
2021$0--$100.1M-$127.9M
2022$0--$223.5M-$176.4M
2023$0--$402.3M-$364.7M
2024$0--$463.9M-$475.1M
2025$0--$766.6M-$669.3M
PeriodGross marginOperating marginNet marginROEROA
20200.0%0.0%0.0%-25.8%-22.7%
20210.0%0.0%0.0%-35.2%-30.9%
20220.0%0.0%0.0%-23.4%-22.2%
20230.0%0.0%0.0%-32.4%-28.6%
20240.0%0.0%0.0%-14.0%-13.2%
20250.0%0.0%0.0%-28.5%-25.2%
PeriodCashDebtNet debtCurrent ratio
2020$386.2M$0-$386.2M8.30
2021$69M$16.8M-$52.2M8.93
2022$834.7M$17.9M-$816.7M23.26
2023$397.5M$29.2M-$368.2M7.54
2024$387.9M$71.1M-$316.8M12.75
2025$174M$228.8M$54.9M7.91
PeriodMarket capEnterprise valueP/SP/E
2020$785M$398.8M0.0-8.9
2021$1.2B$1.2B0.0-12.3
2022$3.1B$2.3B0.0-13.9
2023$6.1B$5.7B0.0-15.2
2024$10B$9.7B0.0-21.5
2025$6.3B$6.3B0.0-8.2
Q3 2024$0
Q4 2024$0
Q1 2025$0
Q2 2025$0
Q3 2025$0
Q4 2025$0
Q1 2026$0
Q2 2026$0
PeriodRevenueGrowthNet incomeFCF
Q3 2024$0--$103.1M-$98.8M
Q4 2024$0--$137.1M-$141.4M
Q1 2025$0--$140.7M-$193M
Q2 2025$0--$166.6M-$101.7M
Q3 2025$0--$212.8M-$155.4M
Q4 2025$0--$246.5M-$219.3M
Q1 2026$0--$320.6M-$295.4M
Q2 2026$0--$284.3M-$532.5M
PeriodGross marginOperating marginNet marginROEROA
Q3 20240.0%0.0%0.0%-3.0%-2.9%
Q4 20240.0%0.0%0.0%-4.1%-3.9%
Q1 20250.0%0.0%0.0%-4.4%-4.2%
Q2 20250.0%0.0%0.0%-5.4%-5.0%
Q3 20250.0%0.0%0.0%-7.4%-6.7%
Q4 20250.0%0.0%0.0%-9.2%-8.1%
Q1 20260.0%0.0%0.0%-10.7%-9.6%
Q2 20260.0%0.0%0.0%-10.3%-9.1%
PeriodCashDebtNet debtCurrent ratio
Q3 2024$1.1B$28M-$1B17.88
Q4 2024$387.9M$71.1M-$316.8M12.75
Q1 2025$346.9M$87.2M-$259.6M17.70
Q2 2025$306.7M$85.8M-$220.9M11.11
Q3 2025$281.1M$84.4M-$196.6M8.83
Q4 2025$174M$228.8M$54.9M7.91
Q1 2026$260.8M$116.3M-$144.5M7.49
Q2 2026$183.2M$115.4M-$67.7M5.72
PeriodMarket capEnterprise valueP/SP/E
Q3 2024$14.1B$13.1B0.0-34.4
Q4 2024$10.1B$9.7B0.0-18.3
Q1 2025$5.1B$4.9B0.0-9.1
Q2 2025$4.4B$4.2B0.0-6.7
Q3 2025$4.9B$4.7B0.0-5.8
Q4 2025$6.3B$6.3B0.0-6.4
Q1 2026$8.1B$8B0.0-6.3
Q2 2026$8.4B$8.3B0.0-7.4

Refreshed 1h ago

Charts: revenue, profit, cash flow & valuation
Revenue$0Q2 2026
Q3 2023: $0Q4 2023: $0Q1 2024: $0Q2 2024: $0Q3 2024: $0Q4 2024: $0Q1 2025: $0Q2 2025: $0Q3 2025: $0Q4 2025: $0Q1 2026: $0Q2 2026: $0Q3 2023Q2 2026
Net income-$284.3MQ2 2026
-$240.5M-$160.3M-$80.2MQ3 2023: -$92.7MQ4 2023: -$180.8MQ1 2024: -$95MQ2 2024: -$128.7MQ3 2024: -$103.1MQ4 2024: -$137.1MQ1 2025: -$140.7MQ2 2025: -$166.6MQ3 2025: -$212.8MQ4 2025: -$246.5MQ1 2026: -$320.6MQ2 2026: -$284.3MQ3 2023Q2 2026
EBITDA-$292.5MQ2 2026
-$236.1M-$157.4M-$78.7MQ3 2023: -$108.9MQ4 2023: -$177.9MQ1 2024: -$91.9MQ2 2024: -$125.2MQ3 2024: -$135.1MQ4 2024: -$52.6MQ1 2025: -$135.8MQ2 2025: -$161.6MQ3 2025: -$209.8MQ4 2025: -$234.6MQ1 2026: -$314.8MQ2 2026: -$292.5MQ3 2023Q2 2026
Free cash flow-$532.5MQ2 2026
-$399.3M-$266.2M-$133.1MQ3 2023: -$64.9MQ4 2023: -$185.9MQ1 2024: -$171.2MQ2 2024: -$166.8MQ3 2024: -$98.8MQ4 2024: -$141.4MQ1 2025: -$193MQ2 2025: -$101.7MQ3 2025: -$155.4MQ4 2025: -$219.3MQ1 2026: -$295.4MQ2 2026: -$532.5MQ3 2023Q2 2026
EPS-$1.97Q2 2026
-$1.72-$1.15-$0.58Q3 2023: -$0.91Q4 2023: -$1.73Q1 2024: -$0.85Q2 2024: -$1.1Q3 2024: -$0.83Q4 2024: -$1.12Q1 2025: -$1.04Q2 2025: -$1.22Q3 2025: -$1.56Q4 2025: -$1.81Q1 2026: -$2.3Q2 2026: -$1.97Q3 2023Q2 2026
Cash / Debt$183.2MQ2 2026
$262.5M$525.1M$787.6M$1.1BQ3 2023 · Cash: $545.1MQ3 2023 · Debt: $13.8MQ4 2023 · Cash: $397.5MQ4 2023 · Debt: $29.2MQ1 2024 · Cash: $611.5MQ1 2024 · Debt: $27.4MQ2 2024 · Cash: $518.7MQ2 2024 · Debt: $25.6MQ3 2024 · Cash: $1.1BQ3 2024 · Debt: $28MQ4 2024 · Cash: $387.9MQ4 2024 · Debt: $71.1MQ1 2025 · Cash: $346.9MQ1 2025 · Debt: $87.2MQ2 2025 · Cash: $306.7MQ2 2025 · Debt: $85.8MQ3 2025 · Cash: $281.1MQ3 2025 · Debt: $84.4MQ4 2025 · Cash: $174MQ4 2025 · Debt: $228.8MQ1 2026 · Cash: $260.8MQ1 2026 · Debt: $116.3MQ2 2026 · Cash: $183.2MQ2 2026 · Debt: $115.4MQ3 2023Q2 2026
CashDebt
Profitability0.0%Q2 2026
Q3 2023 · Gross margin: 0.0%Q4 2023 · Gross margin: 0.0%Q1 2024 · Gross margin: 0.0%Q2 2024 · Gross margin: 0.0%Q3 2024 · Gross margin: 0.0%Q4 2024 · Gross margin: 0.0%Q1 2025 · Gross margin: 0.0%Q2 2025 · Gross margin: 0.0%Q3 2025 · Gross margin: 0.0%Q4 2025 · Gross margin: 0.0%Q1 2026 · Gross margin: 0.0%Q2 2026 · Gross margin: 0.0%Q3 2023 · Operating margin: 0.0%Q4 2023 · Operating margin: 0.0%Q1 2024 · Operating margin: 0.0%Q2 2024 · Operating margin: 0.0%Q3 2024 · Operating margin: 0.0%Q4 2024 · Operating margin: 0.0%Q1 2025 · Operating margin: 0.0%Q2 2025 · Operating margin: 0.0%Q3 2025 · Operating margin: 0.0%Q4 2025 · Operating margin: 0.0%Q1 2026 · Operating margin: 0.0%Q2 2026 · Operating margin: 0.0%Q3 2023 · Net margin: 0.0%Q4 2023 · Net margin: 0.0%Q1 2024 · Net margin: 0.0%Q2 2024 · Net margin: 0.0%Q3 2024 · Net margin: 0.0%Q4 2024 · Net margin: 0.0%Q1 2025 · Net margin: 0.0%Q2 2025 · Net margin: 0.0%Q3 2025 · Net margin: 0.0%Q4 2025 · Net margin: 0.0%Q1 2026 · Net margin: 0.0%Q2 2026 · Net margin: 0.0%Q3 2023Q2 2026
Gross marginOperating marginNet margin
Shares outstanding144.5MQ2 2026
36.1M72.2M108.4M144.5MQ3 2023: 101.7MQ4 2023: 104.4MQ1 2024: 111.7MQ2 2024: 117.3MQ3 2024: 123.7MQ4 2024: 122.8MQ1 2025: 135.7MQ2 2025: 136MQ3 2025: 136.2MQ4 2025: 136.1MQ1 2026: 139.5MQ2 2026: 144.5MQ3 2023Q2 2026
Valuation-7.4Q2 2026
-25.8-17.2-8.6Q3 2023 · P/E: -14.0Q4 2023 · P/E: -9.1Q1 2024 · P/E: -19.6Q2 2024 · P/E: -17.5Q3 2024 · P/E: -34.4Q4 2024 · P/E: -18.3Q1 2025 · P/E: -9.1Q2 2025 · P/E: -6.7Q3 2025 · P/E: -5.8Q4 2025 · P/E: -6.4Q1 2026 · P/E: -6.3Q2 2026 · P/E: -7.4Q3 2023 · P/S: 0.0Q4 2023 · P/S: 0.0Q1 2024 · P/S: 0.0Q2 2024 · P/S: 0.0Q3 2024 · P/S: 0.0Q4 2024 · P/S: 0.0Q1 2025 · P/S: 0.0Q2 2025 · P/S: 0.0Q3 2025 · P/S: 0.0Q4 2025 · P/S: 0.0Q1 2026 · P/S: 0.0Q2 2026 · P/S: 0.0Q3 2023Q2 2026
P/EP/S
Revenue$02025
2018: $02019: $02020: $02021: $02022: $02023: $02024: $02025: $020182025
Net income-$766.6M2025
-$575M-$383.3M-$191.7M2018: -$29.5M2019: -$50.3M2020: -$89.2M2021: -$100.1M2022: -$223.5M2023: -$402.3M2024: -$463.9M2025: -$766.6M20182025
EBITDA-$741.8M2025
-$556.3M-$370.9M-$185.4M2018: -$28.4M2019: -$49M2020: -$87.8M2021: -$96.6M2022: -$214M2023: -$392.1M2024: -$448.1M2025: -$741.8M20182025
Free cash flow-$669.3M2025
-$502M-$334.6M-$167.3M2018: -$32.2M2019: -$48.3M2020: -$47.8M2021: -$127.9M2022: -$176.4M2023: -$364.7M2024: -$475.1M2025: -$669.3M20182025
EPS-$5.632025
-$10.6-$7.05-$3.532018: -$8.122019: -$14.12020: -$2.972021: -$1.932022: -$3.442023: -$4.142024: -$3.82025: -$5.6320182025
Cash / Debt$174M2025
$208.7M$417.3M$626M$834.7M2018 · Cash: $66.1M2018 · Debt: $458K2019 · Cash: $59M2019 · Debt: $161K2020 · Cash: $386.2M2020 · Debt: $02021 · Cash: $69M2021 · Debt: $16.8M2022 · Cash: $834.7M2022 · Debt: $17.9M2023 · Cash: $397.5M2023 · Debt: $29.2M2024 · Cash: $387.9M2024 · Debt: $71.1M2025 · Cash: $174M2025 · Debt: $228.8M20182025
CashDebt
Profitability0.0%2025
2018 · Gross margin: 0.0%2019 · Gross margin: 0.0%2020 · Gross margin: 0.0%2021 · Gross margin: 0.0%2022 · Gross margin: 0.0%2023 · Gross margin: 0.0%2024 · Gross margin: 0.0%2025 · Gross margin: 0.0%2018 · Operating margin: 0.0%2019 · Operating margin: 0.0%2020 · Operating margin: 0.0%2021 · Operating margin: 0.0%2022 · Operating margin: 0.0%2023 · Operating margin: 0.0%2024 · Operating margin: 0.0%2025 · Operating margin: 0.0%2018 · Net margin: 0.0%2019 · Net margin: 0.0%2020 · Net margin: 0.0%2021 · Net margin: 0.0%2022 · Net margin: 0.0%2023 · Net margin: 0.0%2024 · Net margin: 0.0%2025 · Net margin: 0.0%20182025
Gross marginOperating marginNet margin
Shares outstanding136.1M2025
34M68M102.1M136.1M2018: 3.6M2019: 3.8M2020: 29.5M2021: 51.9M2022: 64.9M2023: 97.2M2024: 122M2025: 136.1M20182025
Valuation-8.22025
-16.2-10.8-5.42018 · P/E: -3.22019 · P/E: -1.92020 · P/E: -8.92021 · P/E: -12.32022 · P/E: -13.92023 · P/E: -15.22024 · P/E: -21.52025 · P/E: -8.22018 · P/S: 0.02019 · P/S: 0.02020 · P/S: 0.02021 · P/S: 0.02022 · P/S: 0.02023 · P/S: 0.02024 · P/S: 0.02025 · P/S: 0.020182025
P/EP/S

Next catalyst

Catalysts

Earnings
2026-11-03
Revenue est. $12.5M · Updated 1h ago

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 2026-8.27$25M-6
FY 2027-6.58$87.1M-6
FY 2028-5.95$191.2M-6
FY 20291.50$1.5B-3
FY 20306.03$2.4B-2
Q3 2026-2.14$12.5M-4

Company events

6
2026-11-03EarningsActual - / Estimate -2.14-
2026-08-05EarningsActual -1.97 / Estimate -2.06Beat
2026-05-06EarningsActual -2.3 / Estimate -1.78Miss
2026-02-24EarningsActual -1.8 / Estimate -1.53Miss
2025-11-04EarningsActual -1.56 / Estimate -1.27Miss
2025-08-06EarningsActual -1.22 / Estimate -1.12Miss

Peer comparison

Similar listed perps

Analyst track record

How the analysts covering PCVX have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings49169
Analysts1318
Buy / hold / sell48 / 1 / 0166 / 3 / 0
Upgrades / downgrades / initiations0 / 0 / 00 / 0 / 6
Price targets hit / missed2 / 42 (5%)9 / 130 (6%)
Avg. return after a rating (TipRanks)-35.5%-32.9%
Best / worst call+34.5% / -58.7%+77.0% / -58.7%

After buy calls on this stock: not enough measured cases yet

Latest ratings

DateAnalystCallTarget
Oct 5, 2026Jason GerberryBank of America SecuritiesBuyReiterated$146
Oct 5, 2026Joseph StringerNeedhamBuyReiterated$122
Oct 5, 2026Roger SongJefferiesBuyMaintained$146
Oct 5, 2026Salim SyedMizuho SecuritiesBuyMaintained$163
Oct 5, 2026Seamus FernandezGuggenheimBuyReiterated$125

TipRanks data via FMP · computed Oct 6, 2026 · 49 ratings

Frequently asked questions

Where can I trade PCVX perpetual futures?

Vaxcyte, Inc. (PCVX) perpetual futures trade on 1 crypto venues, including Bitget. PerpEquities compares them by live price, funding rate, open interest and liquidity.

Can I trade PCVX around the clock?

Yes. Unlike the underlying stock, PCVX perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on PCVX perpetuals?

Right now the PCVX perp funding rate is 0.0% annualized (venue median), ranging from 0.0% to 0.0% across 1 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.

How does the PCVX perp price compare to the Vaxcyte, Inc. stock?

The venue-median PCVX perp mark is $65.8 versus a reference stock price of $65.8, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a PCVX perpetual future?

A PCVX perpetual is a derivative that tracks the price of Vaxcyte, Inc. with no expiry date. It lets you take long or short exposure to Vaxcyte, Inc. on crypto venues, around the clock.

What is PCVXUSDT perpetual?

PCVXUSDT is the symbol most crypto exchanges use for the Vaxcyte, Inc. perpetual settled in USDT (Tether). It tracks the PCVX share price through an index, trades 24/7 with leverage and never expires.

Embed this asset

PCVX perpetuals · perpequities.comPCVX perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/pcvx-perp"><img src="https://perpequities.com/badge/pcvx-perp.svg" width="240" height="64" alt="PCVX perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of PCVX perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for PCVX — one email every Sunday.

Watchlist and alerts

Price and funding alerts for PCVX, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X